Department of Clinical Oncology and Chemotherapy Director:ANDO, Yuichi (Professor)

Aiming at improvement the quality of chemotherapy

The department performs high-level outpatient pharmacotherapy for cancers that occur in all organs.

Medical Care System

With the presence of specialists in cancer pharmacotherapy, we perform medical care through cooperation among doctors, nurses and pharmacists of various departments in order to improve the quality of cancer pharmacotherapy throughout the hospital. In addition to receiving consultation from the staff of other clinical departments, we run special beds for inpatients.

Scope of Medical Services

The department performs medical care in cooperation with other clinical departments specializing in organ-specific cancers, such as digestive organ, breast and lung cancers, and runs chemotherapy rooms for outpatients, acts as a palliative care team, arranges for chemotherapy regimens, conducts clinical trials of anticancer drugs, cancer genomic medicine and provides medical staff training relating to chemotherapy.


We provide global-standard chemotherapy for patients with cancers that occur in all organs, cancer genomic medicine and palliative care for patients with cancer symptoms or side effects of treatment. We are also engaged in the development and clinical trial of new anticancer drugs, as well as education and enlightenment on cancer pharmacotherapy for people in various professions working inside and outside the hospital.

Clinical Results

About 50 chemotherapy regimens per day are administered at the chemotherapy room for outpatients. The palliative care team has been responding to 292 requests in total between April 2022 and March 2023.

Specialized Outpatient Clinic

Medical oncology, Cancer genomic medicine, Rare cancer and Palliative care

Other Undertaking and Researches

The department serves as a Designated Cancer Hospital and Core Hospital for Cancer Genomic Medicine. The department promotes the study focusing on the differences of the side effects of anticancer agents among different individuals.